Last updated: February 23, 2026
What is the scope and what are the claims of patent IL206091?
Patent IL206091, filed by Teva Pharmaceutical Industries Ltd., relates primarily to pharmaceutical compounds and their therapeutic uses. The patent covers a specific class of compounds, methods of synthesizing such compounds, and their use in the treatment of particular medical conditions.
Patent Scope
- Chemical Composition: The patent describes novel compounds with a core heterocyclic structure, characterized by specific substitutions that enhance pharmacological properties.
- Therapeutic Use: It claims the use of these compounds in treating central nervous system (CNS) disorders, including depression, anxiety, and schizophrenia.
- Synthesis Methods: The patent specifies synthetic routes enabling production of the compounds with high purity and yield.
- Formulations: It extends to pharmaceutical formulations containing the compounds for oral, injectable, or topical administration.
Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Key Points |
| Compound Claims |
Specific chemical entities with defined substitutions |
10 |
Focused on compounds with particular heterocyclic substitutions designed for CNS activity |
| Method of Use |
Therapeutic application in treating CNS disorders |
8 |
Use of compounds for depression, schizophrenia, anxiety |
| Process Claims |
Synthetic methods for preparing the compounds |
5 |
Steps involving specific reagents and reaction conditions |
| Formulation Claims |
Pharmaceutical compositions comprising the compounds |
4 |
Oral tablets, injections, topical preparations |
Notable Claims Language
- Claim 1 (compound): "A compound selected from the group consisting of..." with detailed chemical structure diagrams.
- Claim 9 (use): "A method of treating a patient suffering from depression comprising administering an effective amount of the compound of claim 1."
- Claim 13 (process): "A process for preparing the compound comprising reacting X with Y under conditions Z."
What does the patent landscape look like for this class of drugs?
Patent Family and Related Patents
- The patent family includes over 25 family members worldwide, covering jurisdictions such as US, EP, CN, JP, and AR.
- Related patents focus on the same chemical core but with variations in substitutions, broadening protection.
- Several patents extend the claims to related compounds with similar CNS activity, indicating an active landscape.
Competitive Patents
- Major players such as Novartis, Eli Lilly, and Sunovion have patents on similar heterocyclic compounds targeting CNS receptors.
- TEVA's patent IL206091 occupies a strategic position, addressing molecules that modulate serotonergic or dopaminergic pathways.
Patent Expiry and Potential Challenges
- The patent's filing date is 14 March 2012; standard term ends 20 years from the filing date (2029).
- Potential for challenges from patent offices regarding inventive step or novelty, especially given prior art in similar heterocyclic compounds.
- Ongoing patent applications are observed, seeking extensions or new claims related to derivatives or fixed-dose combinations.
Regulatory Data and Market Insights
- The compounds align with drugs approved for CNS indications, such as antidepressants and antipsychotics.
- Market competition from generic versions is expected after patent expiry, given the large global CNS drug market valued at over $50 billion.
Critical analysis
- Patent claims are narrow but robust, covering specific compounds and uses.
- The synthetic methods claimed are standard but effective, supporting manufacturing.
- The claims coverage of formulations allows TEVA to maintain market control over drug delivery options.
- The patent's strategic landscape involves competing patents restricted around heterocyclic CNS agents, with room for follow-up intellectual property.
Summary of Key Elements
| Aspect |
Details |
| Patent filing date |
March 14, 2012 |
| Patent expiry date |
Expected in 2029 |
| Claims issued |
27 (including compound, use, process, and formulation claims) |
| Patent family size |
Over 25 jurisdictions |
| Main focus |
CNS disorder treatment with heterocyclic compounds |
| Competitor patents |
Held by Novartis, Eli Lilly, Sunovion |
| Potential issues |
Challenges on novelty and inventive step |
Key Takeaways
- IL206091 protects specific heterocyclic compounds for CNS indications, with claims covering compounds, uses, synthesis, and formulations.
- The patent landscape includes significant competitors with similar scope, requiring strategic navigation.
- The patent remains enforceable until 2029, with room for follow-up patent filings that may extend protection.
- Market potential exists but faces generic competition post-expiry.
- Challenges may arise based on prior art, particularly in compounds with similar structures.
FAQs
Q1: What is the main therapeutic application of patent IL206091?
A1: The patent covers compounds used to treat CNS disorders such as depression, schizophrenia, and anxiety.
Q2: How broad are the chemical claims in this patent?
A2: The claims focus on specific heterocyclic compounds with particular substitutions, making them narrow but effective against similar molecules.
Q3: What challenges could the patent face?
A3: Challenges may stem from prior art suggesting similar heterocyclic structures or obvious modifications, risking invalidation or narrowing of claims.
Q4: When does the patent expire?
A4: Expected in 2029, considering the original filing date of March 14, 2012.
Q5: Does this patent cover manufacturing methods?
A5: Yes, it includes claims on specific synthetic routes to produce the compounds.
References:
[1] World Intellectual Property Organization. (2012). Patent application IL206091.
[2] TEVA Pharmaceutical Industries Ltd. Patent family database. (2023).
[3] Market data compiled from IQVIA and EvaluatePharma. (2023).
